IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS

• US 20100092536A1
• Filed: 05/11/2009
• Published: 04/15/2010
• Est. Priority Date: 11/20/2003
• Status: Abandoned Application

• Current Assignee: Angiotech Pharmaceuticals Incorporated
• Original Assignee: Angiotech Pharmaceuticals Incorporated
• Inventors: Hunter, William L., Toleikis, Philip M., Gravett, David M., Maiti, Arpita
• Application Number:
  US12/464,012
• Publication Number:
  US 20100092536A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61K 38/17 from animals; from humans enzyme inhibitors A61K38/005
• CPC Class Codes: A61L 2300/404 Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/432 Inhibitors, antagonists A61L2300/402 - A61L2300/43 take precedence
• CPC Class Codes: A61L 2300/45 Mixtures of two or more drugs, e.g. synergistic mixtures
• CPC Class Codes: A61L 27/3641 characterised by the site of application in the body materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61N 1/05 for implantation or insertion into the body, e.g. heart electrode A61N1/06 takes precedence
• CPC Class Codes: A61N 1/372 Arrangements in connection with the implantation of stimulators
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

Claims

1. A device, comprising a sensor or a pump and an anti-scarring agent or a composition comprising an anti-scarring agent, wherein the anti-scarring agent inhibits scarring between the device and a host into which the device is implanted.

2. The device of claim 1, wherein the anti-scarring agent is an angiogenesis inhibitor, wherein the anti-scarring agent is an angiogenesis inhibitor, a 5-lipoxygenase inhibitor or antagonist, a chemokine receptor antagonist, a cell cycle inhibitor, a cyclin dependent protein kinase inhibitor, an epidermal growth factor kinase inhibitor, an elastase inhibitor, a factor Xa inhibitor, a farnesyltransferase inhibitor, a fibrinogen antagonist, a guanylate cyclase stimulant, a heat shock protein 90 antagonist, an HMGCoA reductase inhibitor, a hydroorotate dehydrogenase inhibitor, an IKK2 inhibitor, an IL-1 antagonist, an ICE antagonist, an IRAK antagonist, an IL-4 agonist, an immunomodulatory agent, an inosine monophosphate dehydrogenase (IMPDH) inhibitor, a leukotriene inhibitor, an MCP-1 antagonist, an MMP inhibitor, an NF kappa B inhibitor, an NO antagonist, or a p38 MAP kinase inhibitor.

3. The device of claim 1, wherein the anti-scarring agent is a phosphodiesterase inhibitor, a TGF beta inhibitor, a thromboxane A2 antagonist, a TNF alpha antagonist, a tyrosine kinase inhibitor, a vitronectin inhibitor, a fibroblast growth factor inhibitor, a protein kinase inhibitor, a PDGF receptor kinase inhibitor, an endothelial growth factor receptor kinase inhibitor, a retinoic acid receptor antagonist, a platelet derived growth factor receptor kinase inhibitor, a fibrinogen antagonist, an antimycotic agent, a bisphosphonate, a phospholipase A1 inhibitor, a histamine H1/H2/H3 receptor antagonist, a macrolide antibiotic, a GPIIb/IIIa receptor antagonist, an endothelin receptor antagonist, a peroxisome proliferator-activated receptor agonist, an estrogen receptor agent, a somastostatin analogue, or a neurokinin antagonist.

4. The device of claim 1, wherein the anti-scarring agent is a VLA-4 antagonist, an osteoclast inhibitor, a DNA topoisomerase ATP hydrolyzing inhibitor, an angiotensin I converting enzyme inhibitor, an angiotensin II antagonist, an enkephalinase inhibitor, a peroxisome proliferator-activated receptor gamma agonist insulin sensitizer, a protein kinase C inhibitor, a ROCK (rho-associated kinase) inhibitor, a CXCR3 inhibitor, an Itk inhibitor, a PPAR agonist, an immunosuppressant, an Erb inhibitor, an apoptosis agonist, a lipocortin agonist, a VCAM-1 antagonist, a collagen antagonist, an alpha 2 integrin antagonist, a TNF alpha inhibitor, a nitric oxide inhibitor, or a cathepsin inhibitor.

5. The device of claim 1, wherein the anti-scarring agent is paclitaxel or derivative thereof, a fluoropyrimidine analogue, or sirolimus or an analogue or derivative thereof.

6. The device of claim 1, wherein the sensor is a blood or tissue glucose monitor, a pressure or stress sensor, a cardiac sensor, a respiratory sensor, an auditory sensor, or an electrolyte or metabolite sensor.

7. The device of claim 1, wherein the pump is an implantable insulin pump, an intrathecal drug delivery pump, an implantable drug delivery pump, or a drug delivery pump for treating a heart disease.

8. The device of claim 1, further comprising a coating, wherein the coating comprises the anti-scarring agent.

9. The device of claim 8, wherein the coating further comprises a polymer.

10. The device of claim 1, further comprising a second pharmaceutically active agent or a visualization agent.

11. The device of claim 10, wherein the second pharmaceutically active agent is an anti-inflammatory agent, an anti-infective agent, or an anti-thrombotic agent.

12. The device of claim 1, wherein the anti-scarring agent is released in effective concentrations from the device over a period ranging from the time of deployment of the device to about 180 days.

19. The method of claim 1, comprising further placing a second pharmaceutically active agent into the animal host.

20. The method of claim 19, wherein the second pharmaceutically active agent is an anti-inflammatory agent, an anti-infective agent, or an anti-thrombotic agent.

13. A method for making a device, comprising combining a sensor or pump and an anti-scarring agent or a composition comprising an anti-scarring agent, wherein the agent inhibits scarring between the device and a host into which the device is implanted.

14. A method for inhibiting scarring comprising placing a sensor or pump and an anti-scarring agent or a composition comprising an anti-scarring agent into an animal host, wherein the anti-scarring agent inhibits scarring.

15. The method of claim 14, wherein the anti-scarring agent is an angiogenesis inhibitor, wherein the anti-scarring agent is an angiogenesis inhibitor, a 5-lipoxygenase inhibitor or antagonist, a chemokine receptor antagonist, a cell cycle inhibitor, a cyclin dependent protein kinase inhibitor, an epidermal growth factor kinase inhibitor, an elastase inhibitor, a factor Xa inhibitor, a farnesyltransferase inhibitor, a fibrinogen antagonist, a guanylate cyclase stimulant, a heat shock protein 90 antagonist, an HMGCoA reductase inhibitor, a hydroorotate dehydrogenase inhibitor, an IKK2 inhibitor, an IL-1 antagonist, an ICE antagonist, an IRAK antagonist, an IL-4 agonist, an immunomodulatory agent, an inosine monophosphate dehydrogenase (IMPDH) inhibitor, a leukotriene inhibitor, an MCP-1 antagonist, an MMP inhibitor, an NF kappa B inhibitor, an NO antagonist, a p38 MAP kinase inhibitor, a phosphodiesterase inhibitor, a TGF beta inhibitor, a thromboxane A2 antagonist, a TNF alpha antagonist, a tyrosine kinase inhibitor, a vitronectin inhibitor, a fibroblast growth factor inhibitor, a protein kinase inhibitor, a PDGF receptor kinase inhibitor, an endothelial growth factor receptor kinase inhibitor, a retinoic acid receptor antagonist, a platelet derived growth factor receptor kinase inhibitor, a fibrinogen antagonist, an antimycotic agent, a bisphosphonate, a phospholipase A1 inhibitor, a histamine H1/H2/H3 receptor antagonist, a macrolide antibiotic, a GPIIb/IIIa receptor antagonist, an endothelin receptor antagonist, a peroxisome proliferator-activated receptor agonist, an estrogen receptor agent, a somastostatin analogue, a neurokinin antagonist, a VLA-4 antagonist, an osteoclast inhibitor, a DNA topoisomerase ATP hydrolyzing inhibitor, an angiotensin I converting enzyme inhibitor, an angiotensin II antagonist, an enkephalinase inhibitor, a peroxisome proliferator-activated receptor gamma agonist insulin sensitizer, a protein kinase C inhibitor, a ROCK (rho-associated kinase) inhibitor, a CXCR3 inhibitor, an Itk inhibitor, a PPAR agonist, an immunosuppressant, an Erb inhibitor, an apoptosis agonist, a lipocortin agonist, a VCAM-1 antagonist, a collagen antagonist, an alpha 2 integrin antagonist, a TNF alpha inhibitor, a nitric oxide inhibitor, or a cathepsin inhibitor.

16. The method of claim 14, wherein the device is a blood or tissue glucose monitor, a pressure or stress sensor, a cardiac sensor, a respiratory sensor, an auditory sensor, an electrolyte or metabolite sensor, an implantable insulin pump, an intrathecal drug delivery pump, an implantable drug delivery pump, or a drug delivery pump for treating a heart disease.

17. The method of claim 14, wherein the device further comprises a coating, and wherein the coating comprises the anti-scarring agent.

18. The method of claim 17, wherein the coating further comprises a polymer.